While Alzheimer’s Disease (AD) drug development has been littered with late-stage clinical failures, understanding of the disease and the need to treat patients early in the disease process, has advanced considerably in recent years. A central need for AD drug development, clinical diagnosis and disease monitoring has made for better biomarkers of disease onset and progression as well as easy-to-use, affordable diagnostic tools. This has various implications around the ability to screen patients early, diagnose AD and ensure access to treatment.
This panel will explore the critical success factors necessary to prepare the market for AD diagnosis and management, which will require different stakeholders and industries to work together to facilitate change.

Ability Level: Intermediate

Session ID: 19826